After Hours
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility.
Stocks Info
DNLI belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. The current market capitalization of Denali Therapeutics Inc is $3.09B. A total of 1.69 million shares were traded on the day, compared to an average of 882.00K shares.
In the most recent transaction, Ho Carole sold 12,255 shares of DNLI for 20.22 per share on Jan 06 ’25. After the transaction, the Chief Medical Officer now owns 178,580 company shares. In a previous transaction on Jan 07 ’25, Ho Carole sold 2,907 shares at 20.81 per share. DNLI shares that Chief Medical Officer owns now total 175,673.
Among the insiders who sold shares, Schuth Alexander O. disposed of 12,255 shares on Jan 06 ’25 at a per-share price of $20.22. This resulted in the COFO and Secretary holding 247,215 shares of DNLI after the transaction. In another insider transaction, Schuth Alexander O. sold 2,907 shares at $20.81 per share on Jan 07 ’25. Company shares held by the COFO and Secretary now total 244,308.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. In terms of 52-week highs and lows, DNLI has a high of $33.33 and a low of $14.56.
As of this writing, DNLI has an earnings estimate of -$0.84 per share for the current quarter. EPS was calculated based on a consensus of 11.0 estimates, with a high estimate of -$0.69 per share and a lower estimate of -$1.0.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. DNLI’s latest balance sheet shows that the firm has $865.41M in Cash & Short Term Investments as of fiscal 2021. There were $64.01M in debt and $378.25M in liabilities at the time. Its Book Value Per Share was $9.17, while its Total Shareholder’s Equity was $962.29M.
Analysts Opinion
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for DNLI is Buy with a score of 4.89.
